Horizon Discovery Share Discussion Threads

[pjj71] 08/2/2018 12:07

i think it is more than that.. look at the volume.. maybe end of the seller and a corporate buyer hehe

[mamcw] 08/2/2018 11:16

Amazing what an announcement of a capital markets day can do for sentiment - let's hope they have something exciting to say.

[kestelmill] 07/2/2018 14:28

I hope the price goes down much further, then I will get my chequebook out

[largeronald] 07/2/2018 14:01

Missed the boat on these a year ago - never thought I'd get another chance of hopping on board at these prices.

[pjj71] 07/2/2018 09:17

I wish this relentless seller would hurry up dumping their stock!@!!

[pjj71] 06/2/2018 12:43

That's comforting to see!!!

[phowdo] 06/2/2018 11:10

NEDs buy 350k shares.

[pjj71] 06/2/2018 08:32

On a bright note I guess Roche might have a stab at buying them if it falls much further :)

[gnnmartin] 05/2/2018 20:26

I've just looked again at the interim presentation and the pre close update, and noticed that we seem to have gone from "FY17 guidance ... • Group EBITDA approximately break-even before exceptionals and discontinued operations" in the half year presentation to "The Group expects that reported EBITDA before exceptional items and discontinued operations for the full year will be in line with the analyst consensus forecast loss of (£1.7) million" in the pre close RNS. I guess that with the weakness in the markets generally explains the share price fall.

[pjj71] 05/2/2018 12:28

Looks to me an II continues to dump in a very clumsy manner.. probably down to the last of their holding and crashing the price... im buying a bit at 179p and will see where it goes!!!

[kestelmill] 05/2/2018 11:39

Remember last time this happened? Turned out to be an amazing buying opportunity down at ~£1.40. Same again?

[pjj71] 05/2/2018 08:29

what a dog this is turning into again!!!

[beanol] 02/2/2018 16:59

Don't understand reasons for sharp fall. Any ideas anyone?

[pjj71] 02/2/2018 09:02

i think one of the IIs is still offloading at any price.. should bounce back once they have finished trashing the sp!!

[rampmeister] 02/2/2018 08:14

Well I am pretty happy with the update. Revenue has doubled from that reported in first half plus increase in gross margins. Full year only includes 4 month contribution from Dharmicon. So plenty to look forward to and likely swing into profitability with FY loss down to 1.7m. Hoping for fireworks in 2018 year guidance when they report 2017 FY in May. Also notice share price has not increased significantly from last May results so can see some upside here.

RM

[mamcw] 01/2/2018 12:48

The TU is OK, but a bit half-empty. They don't seem to exceed expectations. A sensible company is being built, but the breakthrough into exponential growth isn't quite there.

[pjj71] 01/2/2018 11:23

it seems on track but the trading on this stock is always hard to fathom!!!

[melody9999] 01/2/2018 09:33

Looks like a positive and upbeat TU today.

I particularly like the closing statement: "we are committed to achieving near-term profitability and free cash generation as revenues and margins continue to scale beyond our predominantly fixed cost base"

All seems to be on track to me - any other views?

[mamcw] 15/1/2018 17:05

Interesting couple of days trading. HZD has been rather quiet on the RNS front in terms of partnership / product developments - maybe something exciting is brewing :)

[melody9999] 12/1/2018 13:07

and this morning I suspect we have the answer. 2 large trades of 225K each followed by a price rebound. suspect these were large sales that had dragged the share price down - and presents a buying opportunity.

[melody9999] 08/1/2018 11:51

may - I agree and am perplexed too. Strong update from ABC recently with similar model. Just seems to be drifting on a small number of sells.

[mayflyniall] 02/1/2018 21:14

Anybody got any clues as to the downward movement today? All the news via linkedIn etc seems reasonably positive.

[mamcw] 19/12/2017 12:40

Horizon Discovery enters into agreement with Roche Diagnostics to support the development of immunohistochemistry assays for oncology



· Horizon to develop and manufacture FFPE Reference Standards that express NTRK fusion biomarkers

· Standards to be derived from custom gene edited cell lines

· Agreement builds upon Horizon's pre-existing partnership with Roche Diagnostics



Cambridge, UK, 18 December, 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company"), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.



Under the terms of the agreement, Horizon will develop and provide Reference Standard material expressing neurotrophic tropomyosin receptor kinase (NTRK) fusion biomarkers. NTRK gene rearrangements have recently emerged as promising targets for cancer therapy, and a number of novel compounds have been developed against the fusion proteins that arise from these molecular alterations. Their effective application, however, depends upon the accurate determination of the genotype of patients, which is primarily carried out through IHC-based diagnostic testing.



Horizon's Reference Standards will be derived from cell lines generated using the Company's industry-leading gene editing platform to include knock-ins (KI) of NTRK 1,2 and 3 fusion cDNA (each under the control of multiple promoters), to achieve low to high levels of protein expression in selected cell lines. The cells will be supplied in FFPE (formalin-fixed paraffin embedded) format, thereby mimicking real patient samples for better control of variability across the complete diagnostic workflow. The project is expected to be completed within 12 months.



This agreement builds on the Horizon-Roche partnership announced in September 2016, which comprised the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics, to support the development and validation of IHC assays.



Dr. Darrin M Disley, Chief Executive Officer, Horizon Discovery Group, commented: "Horizon continues to establish itself as a leading supporter of the development and validation of molecular diagnostics by providing reliable and high quality reference standards to assay developers. We are very pleased to announce this agreement, further strengthening our ongoing partnership with Roche, and we look forward to continuing to work alongside them as they develop additional important diagnostic assays in areas of significant need."

[argylerich] 07/12/2017 13:48

Interesting the price takes a dip today when the product it licenses is getting big coverage:

hxxp://www.telegraph.co.uk/science/2017/12/05/genetically-mutated-rats-could-released-britain-solve-rodent/

Also a little on FT Alphaville

[pjj71] 16/11/2017 12:17

whats causing this to get whacked today??